PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
-0.10
Negative D/E (negative equity) is a classic Benjamin Graham red flag. While possibly indicating distressed value, check for hidden liabilities and verify asset quality. Consider examining Current Ratio for immediate solvency.
0.91
Net debt under 1x EBITDA - Very conservative position that Benjamin Graham would endorse. Consider examining Interest Coverage to confirm strong debt service capacity.
No Data
No Data available this quarter, please select a different quarter.
0.79
Current ratio below 0.8 - Danger zone. Walter Schloss would avoid unless clear refinancing path exists. Examine all debt metrics urgently.
No Data
No Data available this quarter, please select a different quarter.